Oramed Pharmaceuticals, Inc. Share Price OTC Bulletin Board
Equities
US68403P1049
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
15/05 | Compugen Names David Silberman CFO | MT |
09/05 | Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 15L 12Cr | Sales 2025 * | 40L 33Cr | Capitalization | 9.34Cr 778.19Cr |
---|---|---|---|---|---|
Net income 2024 * | -40L -33Cr | Net income 2025 * | -1.4Cr -116.59Cr | EV / Sales 2024 * | 62.3 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 23.4 x |
P/E ratio 2024 * |
-23
x | P/E ratio 2025 * |
-6.39
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.73% |
Managers | Title | Age | Since |
---|---|---|---|
Miriam Kidron
FOU | Founder | 83 | 12/02/12 |
Nadav Kidron
CEO | Chief Executive Officer | 50 | 12/02/12 |
Joshua Hexter
COO | Chief Operating Officer | 53 | 14/13/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nadav Kidron
CEO | Chief Executive Officer | 50 | 12/02/12 |
Miriam Kidron
FOU | Founder | 83 | 12/02/12 |
Leonard Sank
BRD | Director/Board Member | 59 | 23/07/23 |
1st Jan change | Capi. | |
---|---|---|
+64.23% | 5.51TCr | |
-2.31% | 4.18TCr | |
+44.36% | 4.02TCr | |
-8.29% | 2.82TCr | |
+11.97% | 2.63TCr | |
-21.16% | 1.89TCr | |
+7.54% | 1.3TCr | |
+27.17% | 1.23TCr | |
+25.72% | 1.22TCr |